Developing a

doi:10.5246/jcps.2024.11.072

Abstract

Abstract:

To improve the efficiency and precision of our pharmacy consultation services, we adopted a "1+X" model based on the PDCA (Plan-Do-Check-Act) cycle. In the initial analysis, we identified factors contributing to suboptimal consultation efficiency. Our approach included a thorough examination of our pharmacy consultation system, encompassing personnel training, consultation promotion, and the refinement of the consultation process. A standardized pharmacy consultation model was devised and continually refined, with a primary focus on infectious diseases. Subsequently, the model expanded to include various medical specialties, fostering multi-disciplinary participation. Since the implementation of the "1+X" pharmacy consultation model, spanning from 2017 to 2022, consultation numbers exhibited a consistent annual growth exceeding 50%. In 2022 alone, 5044 pharmaceutical consultations were conducted, encompassing 3007 standard consultations and 96 expanded consultations across diverse departments such as neurosurgery and neurology. The adoption rate of consultation recommendations reached 89.2%, while the effectiveness of consultation treatments stood at an impressive 76.4%. This success underscored the impact of the "1+X" pharmacy consultation model on enhancing consultation outcomes. Collectively, our model, rooted in the PDCA cycle, not only served as a practical blueprint for pharmacy consultation systems in medical institutions but also provided valuable insights and a robust framework for the professional development and training of clinical pharmacists.

Key words: PDCA cycle method, Cinical pharmacist, Parmacy consultation, Model

Supporting:

Tiantian Xu, Xiaoling Song, Xuanying Chen, Yanni Lv. Developing a "1 + X" pharmaceutical consultation model through the PDCA cycle[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(11): 1001-1011.

Figures/Tables 8

Table 1. Distribution of various types of pharmacy consultations during 2018–2022.

Table 2. Distribution of pharmacy consultations in different clinical specialties in 2022.

References 16

[1]	Health and Wellness Commission of the People’s Republic of China. Notice on Strengthening Pharmacy Management and Transforming the Pharmacy Service Model [EB/OL].
[2]	Peng, G.L.; Xing, X.F.; Jia, L.L.; Wang, Y.H.; Jin, G.L. Han, Y. Current status of pharmacy consultation work in tertiary general hospitals based on literature analysis. Chin. J. Clin. Pharm. 2019, 03, 223–226.
[3]	Zhang, Y.; Yuan, H.L.; Xiao, H.; Tang, Y.J.; Wang, L.Z.; Li, W; Xu, L.T. Construction and application of a quality evaluation system for pharmacy monitoring under the new version of hospital accreditation standards. Clin. Med. Res. Pract. 2022, 11, 92–96.
[4]	Zhang, J.X.; Qian, X.; Xiong, S.J.; Chen, Q.; Bai, X.; Fan, L.Y.; Gao, L.; Li, L.H.; Xie, J. Establishment of a template and evaluation system for clinical pharmacists’ anti-infective consultation opinions. Chin. J. Hospital Pharm. 2020, 06,708–713.
[5]	Zhou, P.X.; Dong, S.J.; Li, X.X.; Yan, Y.Y.; Cheng, Y.C.; Li, H.B.; Shi, W.L.; Xu, X.H.; Ying, Y.Q.; Yang, Y.H.; Wang, Z.T.; Liu, F. Construction of standardized pharmacy consultation model based on PDCA cycle method. Chin. J. hospital pharm. 2022, 20, 2177–2181.
[6]	Su, S.; Lu, Q.Y.; Yang, H.K.; Chen, J.; Liu, J. Application of PDCA cycle method to reduce the error rate of intravenous medication dispensing in a static dispensing cente. J. Pharm. Sci. 2022, 07, 158–160.
[7]	Zhu, L.S.; Ji, X.H.; Kong, M.; Dong, C.; Chang, Y.L.; Lin, M. Analysis of the quality improvement effect of PDCA cycle method for experimental drug management. China Pharm. Ind. 2022, 15, 16–20.
[8]	Wang, W.; Ling, J.; Ni, Z.Y.; Qi, H.X. Analysis of the effect of PDCA cycle method to promote the management of key monitored drugs. J. Pharm. Pract. 2022, 02, 180–183.
[9]	Lourtet-Hascoët, J.; Félicé, M.P.; Bicart-See, A.; Bouige, A.; Giordano, G.; Bonnet, E. Species and antimicrobial susceptibility testing of coagulase-negative staphylococci in periprosthetic joint infections. Epidemiol. Infect. 2018, 146, 1771–1776.
[10]	Gould, F.K.; Brindle, R.; Chadwick, P.R.; Fraise, A.P.; Hill, S.; Nathwani, D.; Ridgway, G.L.; Spry, M.J.; Warren, R.E. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J. Antimicrob. Chemother. 2009, 63, 849–861.
[11]	Brown, N.M.; Brown, E.M.; Brown, N.M.; Goodman, A.L.; Horner, C.; Jenkins, A.; Brown, E.M.; Group, T.G.D. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. J. Antimicrob. Chemother. 2021, 76, 1377–1378.
[12]	Yang, Y.; Zhong, X.; Zhang, C.L.; Zuo, W.; Zou, Y.Z.; Du, L.P.; Yan, X.L.; Hu, Y.; Yang, R.J.; Zhang, B. Analysis and effect evaluation of clinical pharmacists’ participation in infectious disease consultation cases. China Pharm. Affair. 2021, 02, 184–190.
[13]	Lu, Y.Z. Pharmaceutical practice and value of pharmacists under the new medical reform situation. J. Chin. Pharm. Sci. 2018, 27, 630–636.
[14]	Chen, B.; Yang, Z.F.; Qiao, Y.; Wen, A.D. Retrospective analysis of clinical pharmacist consultation cases in a hospital from 2015 to 2016. China Pharm. 2018, 03, 457–460.
[15]	Su, D.; Xu, S.; Wang, J.P. The practice and analysis of clinical pharmacists participating in 358 cases of consultation. China Pharm. 2016, 27, 1571–1574.
[16]	Yuan, L.; Yang, Q.; Xu, X.P.; De, Y.T.; Li, H.G. A pharmacist-led intervention study to improve treatment adherence in patients with chronic obstructive pulmonary disease. J. Chin. Pharm. Sci. 2023, 32, 52.

Developing a "1 + X" pharmaceutical consultation model through the PDCA cycle

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 16

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xiaoming Zhang, Shihui Zhu, Yiwen Gao, Jianxiang Li, Nan Zhang, Guihua Yue. Effect of Huanglian Jiedu Decoction on cardiac endoplasmic reticulum stress in spontaneously hypertensive rats [J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(7): 609-619.
[2]	Xiao Zhang, Chunxing Wu, Bolong Wang. Exploring dosage patterns of Chinese herbal medicine for recurrent headaches: A data mining analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(2): 110-122.
[3]	Zining Peng, Qian Deng, Fanyu Meng, Xingqiang Wang, Nian Liu, Weitian Yan, Jiangyun Peng. Exploring the evolution of animal models for gout and hyperuricemia: A bibliometric analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(11): 1058-1067.
[4]	Yufang Wu, Qingzhi Guo, Rui Li, Shikun Zhang. Solvation dynamics of furazolidone in pure organic solvents and aqueous EDTA disodium salt mixtures: molecular interactions and thermodynamic insights [J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(10): 906-917.
[5]	Wentao Zhu, Wanglong Hong, Miaomiao Zheng, Guoqiang Ma, Aizong Shen. Combination of pembrolizumab and chemotherapy as first-line treatment in advanced triple-negative breast cancer: a cost-effectiveness analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 587-597.
[6]	Yancong Zhao, Li Wang, Jingjing Zeng, Jinghua Li. The structure and antiproliferative activity of the inclusion complex of neoandrographolide/β-cyclodextrin [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(6): 427-434.
[7]	Wenjing Ta, Ruochen Hua, Xingyue Li, Jihong Song, Wen Lu. In vitro blood-brain barrier models from different species: an overview on permeability associated with drug delivery [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 237-249.
[8]	Xinfeng Zou, Haihua Guo, Liangjun Deng, Yuting Yang, Zhengqiang Yuan, Wen Tan. A study of irritable bowel syndrome model construction based on combined factor stimulation [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(3): 180-189.
[9]	Jun Ma, Liangyu Ni, Qiyun Zhu, Zhao Yang, Bin Jiang. Cost-utility of siltuximab injection for idiopathic multicentric Castleman disease (iMCD) in China [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 842-851.
[10]	Suqiong Huang, Jingyuan Wan, Tingting Du, Tao Gong, Jing Zhang, Xinhui Jiang. The relationship between the contents of 13 amino acids in brain tissues and the progression of NAFLD via C57BL/6 model mice [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(6): 441-451.
[11]	Jianwei Dong, Xuejiao Li, Chen Yang, Yanqing Zhang, Huifang Zhou, Yali Li. The antioxidant activity and total phenolic and total flavonoid contents of Pyracantha fortuneana fruit can be improved by solid-state fermentation with Rhizopus oryzae and Penicillium commune [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(6): 452-460.
[12]	Shaohong Luo, Liangliang Dong, Yiyuan Li, Dan Xu, Min Chen. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(3): 253-263.
[13]	Lu Shi, Feng Miao, Guopeng Wang, Wenyan Sun, Yang Liu. A PK/PD model of saxagliptin: to simulate its pharmacokinetics and pharmacodynamics in healthy adults and patients with impaired hepatic function [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(2): 119-132.
[14]	Mengyi Han, Ling Yong, Yuchen Guo, Xiaoxue Yan, Guoshu Chen, Daming Kong, Tianyan Zhou. A stochastic population pharmacodynamic model of QAP14 in the treatment of lung metastases of 4T1 breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(10): 794-805.
[15]	Peili Jiao, Yiyan Li, Xing Wu, Yuxi Wang, Beibei Mao, Hongwei Jin, Lihe Zhang, Liangren Zhang, Zhenming Liu. Structure-based design and biological evaluation of novel mTOR inhibitors as potential anti-cervical agents [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(9): 603-616.